Business
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
PRESS RELEASE AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION Paris, May 19, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the Chinese Patent Office has issued a patent relating to methods of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing COVID-19 (i.e. a medical use patent) with its lead compound ma
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION","length":171,"tagName":"p"},{"type":"text","content":"Paris, May 19, 2025, 8am CET","length":28,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today announced that the Chinese Patent Office has issued a patent relating to methods of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing COVID-19 (i.e. a medical use patent) with its lead compound masitinib. This new Chinese patent provides intellectual property protection for masitinib in this indication until April 2041.","length":410,"tagName":"p"},{"type":"text","content":"As part of a collaborative research agreement with the University of Chicago, AB Science signed an exclusive licensing agreement to conduct research for the prevention and treatment of COVID-19 with masitinib and other AB Science proprietary drugs [1]. In case of commercialization in viral disease, AB Science will benefit from an exclusive, royalty-bearing license on any discoveries made with AB Science products (1% of net sales on first registered product and 0.3% of net sales on further registered product to be paid to the University of Chicago).","length":554,"tagName":"p"},{"type":"text","content":"The patent is based in part on preclinical data that has been published in the world-renowned journal Science, and which identified masitinib as a broad antiviral agent capable of treating SARS-CoV-2 (the virus that causes COVID-19), including demonstration of in vivo activity in mice, with efficacy maintained, in vitro, against SARS-CoV-2 variants of concern [2].","length":366,"tagName":"p"},{"type":...